GlaxoSmithKline plc (LON:GSK) has earned an average recommendation of “Hold” from the twenty-two analysts that are covering the stock, Marketbeat.com reports. Four investment analysts have rated the stock with a sell recommendation, ten have assigned a hold recommendation and eight have assigned a buy recommendation to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is GBX 1,722.70 ($22.43).
A number of brokerages have recently weighed in on GSK. Berenberg Bank lowered their price target on GlaxoSmithKline plc from GBX 1,885 ($24.55) to GBX 1,835 ($23.90) and set a “buy” rating for the company in a report on Wednesday. Goldman Sachs Group, Inc. (The) set a GBX 1,900 ($24.74) price objective on GlaxoSmithKline plc and gave the company a “buy” rating in a research report on Tuesday, August 8th. Deutsche Bank AG set a GBX 1,610 ($20.97) price objective on GlaxoSmithKline plc and gave the company a “neutral” rating in a research report on Tuesday, August 8th. UBS AG set a GBX 1,600 ($20.84) price objective on GlaxoSmithKline plc and gave the company a “neutral” rating in a research report on Tuesday, August 1st. Finally, Shore Capital restated a “hold” rating on shares of GlaxoSmithKline plc in a research report on Friday, July 28th.
GlaxoSmithKline plc (LON:GSK) traded down 0.57% during trading on Friday, reaching GBX 1475.00. 6,693,196 shares of the company’s stock traded hands. GlaxoSmithKline plc has a one year low of GBX 1,446.50 and a one year high of GBX 1,745.56. The firm’s market capitalization is GBX 72.10 billion. The company has a 50-day moving average price of GBX 1,589.13 and a 200 day moving average price of GBX 1,623.61.
The business also recently announced a dividend, which will be paid on Thursday, October 12th. Stockholders of record on Thursday, August 10th will be given a dividend of GBX 19 ($0.25) per share. This represents a dividend yield of 1.23%. The ex-dividend date of this dividend is Thursday, August 10th.
In related news, insider Victoria Whyte sold 4,820 shares of the company’s stock in a transaction on Tuesday, June 20th. The stock was sold at an average price of GBX 1,693 ($22.05), for a total transaction of £81,602.60 ($106,267.22). Also, insider Patrick Vallance purchased 861 shares of the company’s stock in a transaction that occurred on Friday, July 14th. The shares were acquired at an average cost of GBX 1,618 ($21.07) per share, for a total transaction of £13,930.98 ($18,141.66). Insiders have bought 3,151 shares of company stock worth $5,054,922 over the last ninety days.
About GlaxoSmithKline plc
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with MarketBeat.com's FREE daily email newsletter.